Dr. Willard Dere is a recognized expert in biotech, pharma, and personalized medicine.

Dr. Dere most recently served as Associate Vice President for Research, and Professor of Internal Medicine at the University of Utah Health Sciences Center from 2014 to 2022. Prior to re-joining academia in 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. He joined Eli Lilly in 1989 and held numerous global roles in clinical pharmacology, regulatory affairs, and both early-stage translational and late-stage clinical research. He moved to Amgen in 2003 where he held multiple roles including head of global development, international medical, and both corporate and international Chief Medical Officer.

Dr. Dere led the clinical development of raloxifene, rPTH 1-34, denosumab, and other drugs in oncology, inflammation, and nephrology. Dr. Dere received a B.A. degree in Zoology and History and an M.D. degree from the University of California, Davis.